【摘要】：目的探討胃間質(zhì)瘤(GSTs)組織中成纖維細(xì)胞活化蛋白(FAP)的表達(dá)情況及其與預(yù)后的相關(guān)性。方法收集2010年1月至2013年12月間我院病理科保存的GSTs石蠟標(biāo)本,通過(guò)免疫組化染色檢測(cè)FAP表達(dá);另取GSTs高、低惡性度患者新鮮腫瘤組織,進(jìn)行FAP蛋白芯片分析,分析FAP與腫瘤臨床病理特點(diǎn)及患者預(yù)后間的關(guān)系。結(jié)果本研究共納入98例符合標(biāo)準(zhǔn)的病例,通過(guò)免疫組化染色顯示FAP表達(dá)于GSTs細(xì)胞的胞漿,陽(yáng)性表達(dá)率為42.9%,在正常胃組織中不表達(dá)。在不同性別、年齡及核分裂象數(shù)的患者中,FAP表達(dá)差異無(wú)統(tǒng)計(jì)學(xué)意義(P均0.05);而在不同腫瘤長(zhǎng)徑和危險(xiǎn)度分級(jí)患者中,FAP表達(dá)差異有統(tǒng)計(jì)學(xué)意義(P均0.05),長(zhǎng)徑較大和中高危險(xiǎn)度分級(jí)的腫瘤,FAP陽(yáng)性表達(dá)率更高。FAP蛋白芯片分析結(jié)果顯示,高惡性度GSTs組織中FAP表達(dá)量較在低惡性度GSTs組織的表達(dá)上調(diào)8.4倍。FAP表達(dá)與常規(guī)免疫組化指標(biāo)之間無(wú)明顯關(guān)聯(lián)性。生存分析示:核分裂象數(shù)、腫瘤長(zhǎng)徑、術(shù)后服用伊馬替尼(IM)及FAP表達(dá),影響中高危GSTs患者無(wú)復(fù)發(fā)累積生存率(RFS)(P均0.05)。Cox多因素回歸示:核分裂象數(shù)、腫瘤長(zhǎng)徑、術(shù)后服用IM及FAP表達(dá),是影響中高危GSTs患者RFS的獨(dú)立因素(P均0.05)。結(jié)論 FAP表達(dá)于GSTs細(xì)胞的胞漿,而在正常胃組織中不表達(dá)。FAP可輔助評(píng)估中高危GSTs患者的預(yù)后。
[Abstract]:Objective to investigate the expression of fibroblast activating protein (FAP) in gastric stromal tumors (GSTs) and its correlation with prognosis. Methods the paraffin specimens of GSTs from January 2010 to December 2013 were collected and the expression of FAP was detected by immunohistochemical staining, and the fresh tumor tissues of patients with high and low grade GSTs were collected for FAP protein chip analysis. To analyze the relationship between FAP and clinicopathological features and prognosis of tumor. Results 98 cases were included in this study. Immunohistochemical staining showed that FAP was expressed in the cytoplasm of GSTs cells. The positive rate of FAP expression was 42.9%, but not in normal gastric tissue. In different genders, There was no significant difference in the expression of FAP in patients with age and mitotic number (P 0.05), but there was a significant difference in the expression of FAP in patients with different tumor length and risk grade (P 0.05). The positive expression rate of FAP in tumor was higher. The results of FAP protein chip analysis showed that The expression of FAP in high grade GSTs was 8.4-fold higher than that in low-grade GSTs. There was no significant correlation between FAP expression and routine immunohistochemical markers. Survival analysis showed that mitotic number, long diameter of tumor, expression of imatinib (IM) and FAP after operation affected cumulative survival rate (RFS) of patients with moderate and high risk GSTs (P 0.05). The expression of IM and FAP were independent factors of RFS in patients with moderate and high risk GSTs (P 0.05). Conclusion FAP is expressed in the cytoplasm of GSTs cells, but not in normal gastric tissues. FAP can be used to evaluate the prognosis of high risk GSTs patients.
【作者單位】： 四川大學(xué)華西醫(yī)院胃腸外科;
【基金】：國(guó)家自然科學(xué)基金(No.81572931)資助
【分類號(hào)】：R735.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 于書奎,胡金安,陳學(xué)志,付風(fēng)魁,鞏曰紅,張曉;胃間質(zhì)瘤二例[J];臨床放射學(xué)雜志;2001年03期

2 王志;胃間質(zhì)瘤2例診斷與治療[J];醫(yī)師進(jìn)修雜志;2002年04期

3 李俊霞 ,王化虹 ,謝鵬雁 ,劉新光 ,柳平 ,余靖;胃間質(zhì)瘤31例臨床分析[J];中華內(nèi)科雜志;2002年11期

4 劉曉冬,曾冬竹,吳淼;兒童胃間質(zhì)瘤一例[J];消化外科;2004年02期

5 饒健章,唐令超;胃間質(zhì)瘤的診斷和治療[J];中國(guó)實(shí)用外科雜志;2004年04期

6 鄭成竹,李際輝;胃間質(zhì)瘤的診斷和微創(chuàng)治療[J];中國(guó)普外基礎(chǔ)與臨床雜志;2004年03期

7 謝正元,錢振育;胃間質(zhì)瘤3例[J];中國(guó)內(nèi)鏡雜志;2004年06期

8 董英,崔卓敏,郭東亮,胡建珩,苗曉敏;胃間質(zhì)瘤超聲表現(xiàn)1例[J];中國(guó)超聲診斷雜志;2004年09期

9 蔡培強(qiáng),謝傳淼,伍堯泮,張偉章;胃間質(zhì)瘤的螺旋CT表現(xiàn)及診斷分析[J];廣州醫(yī)藥;2004年06期

10 李彩霞,劉武韜,邸旭,李倉(cāng)秋,孫志軍;胃間質(zhì)瘤的診療體會(huì)[J];臨床誤診誤治;2005年05期

相關(guān)會(huì)議論文 前10條

1 施春雷;;超聲診斷15例胃間質(zhì)瘤分析[A];中華醫(yī)學(xué)會(huì)第十次全國(guó)超聲醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2009年

2 吳乃森;董發(fā)進(jìn);王剛平;付金棟;徐延峰;;經(jīng)腹超聲對(duì)比顯像診斷胃間質(zhì)瘤的臨床價(jià)值[A];中國(guó)超聲醫(yī)學(xué)工程學(xué)會(huì)第八屆全國(guó)腹部超聲學(xué)術(shù)會(huì)議論文匯編[C];2010年

3 陸文明;;實(shí)時(shí)超聲診斷胃間質(zhì)瘤的臨床價(jià)值[A];中國(guó)超聲醫(yī)學(xué)工程學(xué)會(huì)第七屆全國(guó)腹部超聲學(xué)術(shù)會(huì)議學(xué)術(shù)論文匯編[C];2007年

4 楊，

本文編號(hào)：2119894